Sifting through countless of stocks in the Life Sciences Tools & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in AbCellera Biologics Inc. or Sotera Health Company because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how AbCellera Biologics Inc. and Sotera Health Company compare based on key financial metrics to determine which better meets your investment needs.

About AbCellera Biologics Inc. and Sotera Health Company

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.

Latest Life Sciences Tools & Services and AbCellera Biologics Inc., Sotera Health Company Stock News

As of July 31, 2026, AbCellera Biologics Inc. had a $1.7 billion market capitalization, compared to the Life Sciences Tools & Services median of $1.8 million. AbCellera Biologics Inc.’s stock is up 67% in 2026, up 7.5% in the previous five trading days and up 24.95% in the past year.

Currently, AbCellera Biologics Inc. does not have a price-earnings ratio. AbCellera Biologics Inc.’s trailing 12-month revenue is $79.2 million with a -181.7% net profit margin. Year-over-year quarterly sales growth most recently was 97.6%. Analysts expect adjusted earnings to reach $-0.650 per share for the current fiscal year. AbCellera Biologics Inc. does not currently pay a dividend.

As of July 31, 2026, Sotera Health Company had a $5.1 billion market cap, putting it in the 67th percentile of all stocks. Sotera Health Company’s stock is up 1.2% in 2026, up 2.9% in the previous five trading days and up 49.9% in the past year.

Currently, Sotera Health Company’s price-earnings ratio is 43.8. Sotera Health Company’s trailing 12-month revenue is $1.2 billion with a 9.9% net profit margin. Year-over-year quarterly sales growth most recently was 10.0%. Analysts expect adjusted earnings to reach $0.966 per share for the current fiscal year. Sotera Health Company does not currently pay a dividend.

How We Compare AbCellera Biologics Inc. and Sotera Health Company Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at AbCellera Biologics Inc. and Sotera Health Company’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

AbCellera Biologics Inc. and Sotera Health Company Growth Grades

Company	Ticker	Growth
AbCellera Biologics Inc.	ABCL	F
Sotera Health Company	SHC	B

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

AbCellera Biologics Inc. has a Growth Score of 10, which is Very Weak. Sotera Health Company has a Growth Score of 73, which is Strong.

The Growth Grade Winner: Sotera Health Company

As you can clearly see from the Growth Grade breakdown above, Sotera Health Company has a more attractive growth grade than AbCellera Biologics Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Sotera Health Company could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

AbCellera Biologics Inc. and Sotera Health Company’s Momentum Grades

Company	Ticker	Momentum
AbCellera Biologics Inc.	ABCL	A
Sotera Health Company	SHC	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

AbCellera Biologics Inc. has a Momentum Score of 81, which is Very Strong. Sotera Health Company has a Momentum Score of 81, which is Very Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both AbCellera Biologics Inc. and Sotera Health Company have a grade of A. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

AbCellera Biologics Inc. and Sotera Health Company’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
AbCellera Biologics Inc.	ABCL	B
Sotera Health Company	SHC	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

AbCellera Biologics Inc. has a Earnings Estimate Score of 67, which is Positive. Sotera Health Company has a Earnings Estimate Score of 50, which is Neutral.

The Earnings Estimate Revisions Grade Winner: AbCellera Biologics Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, AbCellera Biologics Inc. has a better Earnings Estimate Revisions Grade than Sotera Health Company. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, AbCellera Biologics Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other AbCellera Biologics Inc. and Sotera Health Company Grades

In addition to Growth, Estimate Revisions and Momentum, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether AbCellera Biologics Inc. and Sotera Health Company pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, AbCellera Biologics Inc. or Sotera Health Company Stock?

Overall, AbCellera Biologics Inc. stock has a Growth Score of 10, Momentum Score of 81 and Estimate Revisions Score of 67.

Sotera Health Company stock has a Growth Score of 73, Momentum Score of 81 and Estimate Revisions Score of 50.

Comparing AbCellera Biologics Inc. and Sotera Health Company’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.